Understanding what constitutes normal variation versus problematic symptoms can help you manage treatment more effectively
However, both companies cannot sell the drug in India until Novo Nordisk loses its patent-exclusivity rights in the country in March 2026
Semaglutide mimics a gut hormone, GLP-1, thats secreted after people eat
Key areas to watch include: Improved drug formulations with extended-release options Combination therapies involving GLP-1 agonists Personalized treatment plans enhanced by genetic profiling Expansion of GLP-1 applications to other metabolic health conditions Advancements in these areas may lead to better treatment adherence and effectiveness
Post-Injection Care After administering Semaglutide, caring for the injection site helps maintain skin health and comfort: Monitor the Area : Its normal to see slight redness or swelling immediately after the injection, which should subside quickly
Word was out that Ousia didn't have a sterile compounding license